Friday, 20 November 2026European Markets

HYLORIS Stock Was Up By 20.84% Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - The Market ended the session with HYLORIS (HYL.BR) jumping 20.84% to €5.74 on Monday, after five consecutive sessions in a row of losses. BEL 20 slid 0.01% to €4,244.62, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

HYLORIS's last close was €4.75, 66.31% under its 52-week high of €14.10.

About HYLORIS

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium.

Earnings Per Share

As for profitability, HYLORIS has a trailing twelve months EPS of €-0.55.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -33.08%.

More news about HYLORIS (HYL.BR).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 16 Sept 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›